Investigational drugs for allergic rhinitis

被引：6

作者：

Passalacqua, Giovanni ^{[1
]}

Compalati, Enrico ^{[1
]}

Canonica, Giorgio Walter ^{[1
]}

机构：

[1] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2010年 / 19卷 / 01期

关键词：

allergen-specific immunotherapy; allergic rhinitis; inflammation; monoclonal antibodies; QUALITY-OF-LIFE; SUBLINGUAL IMMUNOTHERAPY; ANTI-IGE; SUPLATAST TOSILATE; PEDIATRIC-PATIENTS; CLINICAL-TRIALS; DOUBLE-BLIND; ARIA UPDATE; ASTHMA; EFFICACY;

D O I：

10.1517/13543780903435647

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Allergic rhinitis (AR) is a high-prevalence disease, triggered by an IgE-mediated reaction, and sustained by a complex inflammatory network of cells, mediators, and cytokines. When the exposure to allergens persists, the inflammatory process becomes chronic. The current therapeutic strategy is based on allergen avoidance when possible, drugs and allergen immunotherapy. The main drugs are oral and topical antihistamines and nasal steroids. They are overall effective in controlling symptoms, but do not modify the immune background that leads to allergic inflammation. In addition, safety concerns may be present, especially for prolonged treatments. Thus, efforts are currently made to improve the existing molecules and to develop new drugs, in order to achieve greater clinical efficacy with a better tolerability. Also, attempts are made to selectively block relevant signal pathways of the allergic reaction by means of specific anti-mediators. Specific immunotherapy, in addition to the clinical effect, is capable of modifying the Th2-biased immune response. Thus, an intense research activity is presently ongoing with the aim of improving the characteristics and modes of action of this treatment.

引用

页码：93 / 103

页数：11

共 92 条

[1] Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis [J].

Ädelroth, E ;

Rak, S ;

Haahtela, T ;

Aasand, G ;

Rosenhall, L ;

Zetterstrom, O ;

Byrne, A ;

Champain, K ;

Thirlwell, J ;

Della Cioppa, G ;

Sandström, T .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (02) :253-259

[2]

AHLSTROM L, 2007, RESP MED, V101, P1106

[3] Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis [J].

Ahlström-Emanuelsson, C ;

Andersson, M ;

Persson, C ;

Schrewelius, C ;

Greiff, L .

CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (05) :731-735

[4] The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation [J].

Annunziato, Francesco ;

Cosmi, Lorenzo ;

Liotta, Francesco ;

Maggi, Enrico ;

Romagnani, Sergio .

INTERNATIONAL IMMUNOLOGY, 2008, 20 (11) :1361-1368

[5]

Atkinson D. A., 2004, Journal of Allergy and Clinical Immunology, V113, pS175, DOI 10.1016/j.jaci.2004.01.064

[6] ARIA-suggested drugs for allergic rhinitis:: what impact on quality of life?: A GA2LEN review [J].

Baiardini, I. ;

Braido, F. ;

Tarantini, F. ;

Porcu, A. ;

Bonini, S. ;

Bousquet, P. -J. ;

Zuberbier, T. ;

Demoly, P. ;

Canonica, G. W. .

ALLERGY, 2008, 63 (06) :660-669

[7]

Berger WE, 2006, ALLERGY ASTHMA PROC, V27, pS29

[8] Important research questions in allergy and related diseases:: nonallergic rhinitis:: a GA2LEN paper [J].

Bousquet, J. ;

Fokkens, W. ;

Burney, P. ;

Durham, S. R. ;

Bachert, C. ;

Akdis, C. A. ;

Canonica, G. W. ;

Dahlen, S. -E. ;

Zuberbier, T. ;

Bieber, T. ;

Bonini, S. ;

Bousquet, P. J. ;

Brozek, J. L. ;

Cardell, L. -O. ;

Crameri, R. ;

Custovic, A. ;

Demoly, P. ;

van Wijk, R. G. ;

Gjomarkaj, M. ;

Holland, C. ;

Howarth, P. ;

Humbert, M. ;

Johnston, S. L. ;

Kauffmann, F. ;

Kowalski, M. L. ;

Lambrecht, B. ;

Lehmann, S. ;

Leynaert, B. ;

Lodrup-Carlsen, K. ;

Mullol, J. ;

Niggemann, B. ;

Nizankowska-Mogilnicka, E. ;

Papadopoulos, N. ;

Passalacqua, G. ;

Schuenemann, H. J. ;

Simon, H. -U. ;

Todo-Bom, A. ;

Toskala, E. ;

Valenta, R. ;

Wickman, M. ;

Zock, J. P. .

ALLERGY, 2008, 63 (07) :842-853

[9] Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen) [J].

Bousquet, J. ;

Khaltaev, N. ;

Cruz, A. A. ;

Denburg, J. ;

Fokkens, W. J. ;

Togias, A. ;

Zuberbier, T. ;

Baena-Cagnani, C. E. ;

Canonica, G. W. ;

van Weel, C. ;

Agache, I. ;

Ait-Khaled, N. ;

Bachert, C. ;

Blaiss, M. S. ;

Bonini, S. ;

Boulet, L. -P. ;

Bousquet, P. -J. ;

Camargos, P. ;

Carlsen, K. -H. ;

Chen, Y. ;

Custovic, A. ;

Dahl, R. ;

Demoly, P. ;

Douagui, H. ;

Durham, S. R. ;

van Wijk, R. Gerth ;

Kalayci, O. ;

Kaliner, M. A. ;

Kim, Y. -Y. ;

Kowalski, M. L. ;

Kuna, P. ;

Le, L. T. T. ;

Lemiere, C. ;

Li, J. ;

Lockey, R. F. ;

Mavale-Manuel, S. ;

Meltzer, E. O. ;

Mohammad, Y. ;

Mullol, J. ;

Naclerio, R. ;

Hehir, R. E. O. ;

Ohta, K. ;

Ouedraogo, S. ;

Palkonen, S. ;

Papadopoulos, N. ;

Passalacqua, G. ;

Pawankar, R. ;

Popov, T. A. ;

Rabe, K. F. ;

Rosado-Pinto, J. .

ALLERGY, 2008, 63 :8-+

[10] Characteristics of intermittent and persistent allergic rhinitis:: DREAMS study group [J].

Bousquet, J ;

Annesi-Maesano, I ;

Carat, F ;

Léger, D ;

Rugina, M ;

Pribil, C ;

El Hasnaoui, A ;

Chanal, I .

CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (06) :728-732

← 1 2 3 4 5 6 7 8 9 10 →